Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 20.20
- Piotroski Score 1.00
- Grade Buy
- Symbol (AVXL)
- Company Anavex Life Sciences Corp.
- Price $5.67
- Changes Percentage (-0.18%)
- Change -$0.01
- Day Low $5.56
- Day High $5.88
- Year High $10.45
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $11.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.50
- Trailing P/E Ratio -7.74
- Forward P/E Ratio -7.74
- P/E Growth -7.74
- Net Income $-47,491,000
Income Statement
Quarterly
Annual
Latest News of AVXL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company
Individual investors have significant control over Anavex Life Sciences, holding 59% ownership, giving them power to influence management decisions. Institutional investors make up 38%, with no domina...
By Yahoo! Finance | 2 months ago